|
Avaliação DCF da Aclaris Therapeutics, Inc. (ACRS) |
Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
Design Profissional: Modelos Confiáveis E Padrão Da Indústria
Pré-Construídos Para Uso Rápido E Eficiente
Compatível com MAC/PC, totalmente desbloqueado
Não É Necessária Experiência; Fácil De Seguir
Aclaris Therapeutics, Inc. (ACRS) Bundle
Economize tempo e melhore a precisão com a nossa calculadora DCF (ACRS)! Utilizando dados reais da Aclaris Therapeutics, Inc. e suposições personalizáveis, essa ferramenta o capacita a prever, analisar e valorizar (ACRS) como um investidor experiente.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.5 | 6.8 | 29.8 | 31.2 | 18.7 | 22.0 | 25.8 | 30.2 | 35.5 | 41.6 |
| Revenue Growth, % | 0 | 4.3 | 340.05 | 5.03 | -40.09 | 17.31 | 17.31 | 17.31 | 17.31 | 17.31 |
| EBITDA | -48.2 | -65.1 | -84.4 | -117.6 | -51.7 | -22.0 | -25.8 | -30.2 | -35.5 | -41.6 |
| EBITDA, % | -743.52 | -962.28 | -283.53 | -376.22 | -276.28 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 1.3 | .9 | .8 | .9 | .8 | 1.9 | 2.3 | 2.6 | 3.1 | 3.6 |
| Depreciation, % | 20.43 | 13.65 | 2.68 | 2.76 | 4.31 | 8.77 | 8.77 | 8.77 | 8.77 | 8.77 |
| EBIT | -49.5 | -66.0 | -85.2 | -118.4 | -52.5 | -22.0 | -25.8 | -30.2 | -35.5 | -41.6 |
| EBIT, % | -763.95 | -975.94 | -286.21 | -378.98 | -280.59 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 54.1 | 225.7 | 229.8 | 119.1 | 113.6 | 22.0 | 25.8 | 30.2 | 35.5 | 41.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .8 | .6 | .5 | .3 | .3 | 1.1 | 1.3 | 1.5 | 1.8 | 2.1 |
| Account Receivables, % | 11.91 | 9.21 | 1.63 | 0.95363 | 1.7 | 5.08 | 5.08 | 5.08 | 5.08 | 5.08 |
| Inventories | .0 | -34.2 | -12.2 | .0 | .0 | -6.2 | -7.3 | -8.5 | -10.0 | -11.7 |
| Inventories, % | 0 | -506.46 | -41.15 | 0 | 0 | -28.23 | -28.23 | -28.23 | -28.23 | -28.23 |
| Accounts Payable | 5.3 | 10.0 | 10.4 | 8.9 | 4.7 | 11.8 | 13.9 | 16.3 | 19.1 | 22.4 |
| Accounts Payable, % | 81.06 | 147.69 | 34.79 | 28.41 | 25.05 | 53.86 | 53.86 | 53.86 | 53.86 | 53.86 |
| Capital Expenditure | -.5 | -.3 | -.6 | -1.3 | -.1 | -.8 | -.9 | -1.1 | -1.3 | -1.5 |
| Capital Expenditure, % | -6.99 | -4.56 | -2.03 | -4.19 | -0.64637 | -3.68 | -3.68 | -3.68 | -3.68 | -3.68 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -49.3 | -83.0 | -86.9 | -117.9 | -52.5 | -21.9 | -25.7 | -30.2 | -35.4 | -41.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.0 | -43.2 | -108.2 | -131.9 | -56.0 | -8.3 | -21.5 | -25.2 | -29.6 | -34.7 |
| WACC, % | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 | 6.71 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -95.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -35 | |||||||||
| Terminal Value | -751 | |||||||||
| Present Terminal Value | -543 | |||||||||
| Enterprise Value | -638 | |||||||||
| Net Debt | -25 | |||||||||
| Equity Value | -614 | |||||||||
| Diluted Shares Outstanding, MM | 77 | |||||||||
| Equity Value Per Share | -7.94 |
What You Will Get
- Real ACRS Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Aclaris Therapeutics' future performance.
- User-Friendly Interface: Designed for professionals while remaining approachable for newcomers.
Key Features
- 🔍 Real-Life ACRS Financials: Pre-filled historical and projected data for Aclaris Therapeutics, Inc. (ACRS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Aclaris's intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Aclaris's valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the prebuilt Excel template with Aclaris Therapeutics' data included.
- Step 2: Explore the pre-filled sheets and understand the key metrics.
- Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly view recalculated results, including Aclaris Therapeutics' intrinsic value.
- Step 5: Make informed investment decisions or generate reports using the outputs.
Why Choose This Calculator for Aclaris Therapeutics, Inc. (ACRS)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
- Accurate Data: Aclaris Therapeutics' historical and projected financials are preloaded for precision.
- Flexible Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth navigation through the process.
Who Should Use This Product?
- Investors: Evaluate Aclaris Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation methodologies and assess financial forecasts.
- Startup Founders: Understand the valuation strategies of established biotech companies like Aclaris Therapeutics.
- Consultants: Provide expert valuation analyses and reports for client projects.
- Students and Educators: Utilize current data to learn and teach valuation practices in the biotech sector.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Aclaris Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models presenting intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to facilitate analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Aclaris Therapeutics, Inc. (ACRS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions for easy result analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.